OX40R binding agents
US7858765B2 · kind B2 · utility
9Cited by
4References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 24, 2009 |
| Grant date | Dec 28, 2010 |
| Priority date | — |
| Expiry date | Nov 24, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2799/021
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides, fusion proteins comprising them, as well as peptides and other molecules designed on their sequences, can be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.